● Recruiting

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

Condition: Hypogammaglobulinemia · Bacterial Infections · B-cell Chronic Lymphocytic Leukemia · Sponsor: Grifols Therapeutics LLC

PhasePhase 3

Planned participants386

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections per participant per year in B-cell CLL, MM, and NHL participants with hypogammaglobulinemia (HGG) in comparison to the Placebo plus SMT group.

This description comes directly from the study's public registry record.

Talk to the study team

Karen Pellath · +1 9194337967 · karen.pellath@grifols.com

Marina Acosta Enslen · marina.acostaenslen@grifols.com

Always discuss trial participation with your own doctor first.

Locations (62)

GC2202 Study Site 115	Huntington Park, California, United States	Recruiting
GC2202 Study Site 103	St. Petersburg, Florida, United States	Recruiting
GC2202 Study Site 111	Bethesda, Maryland, United States	Recruiting
GC2202 Study Site 109	Greenville, North Carolina, United States	Recruiting
GC2202 Decentralized Study Site 114	Morrisville, North Carolina, United States	Recruiting
GC2202 Study Site 105	Canton, Ohio, United States	Recruiting
GC2202 Study Site 110	Rockville, South Carolina, United States	Withdrawn
GC2202 Study Site 702	Banja Luka, Bosnia and Herzegovina	Recruiting
GC2202 Study Site 703	Mostar, Bosnia and Herzegovina	Recruiting
GC2202 Study Site 701	Sarajevo, Bosnia and Herzegovina	Not Yet Recruiting
GC2202 Study Site 202	Burgas, Bulgaria	Recruiting
GC2202 Study Site 203	Plovdiv, Bulgaria	Recruiting

+ 50 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05645107